Abstract: There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed.

Abstract: There is provided in accordance with embodiments of the invention a method of treating or reducing the effects in a subject of a condition selected from fructose intolerance and impaired fructose metabolism, the method comprising administering to a subject in need of such treatment or reduction an efficacious amount of a glucose isomerase, other than in combination with 5-D-fructose dehydrogenase. Other embodiments are also disclosed. There is provided a method for treating or reducing the effects of fructose intolerance and health problems associated with excessive fructose intake by administration of glucose isomerase. Other embodiments are also disclosed.

Abstract: A medical adsorbent for oral administration that has low dosage and excellent adsorptive capacity and selective adsorption for toxins to be removed, and is also economical and environmentally friendly. The medical adsorbent comprises granular activated carbon that is activated carbon obtained by carbonization and activation of refined cellulose or regenerated cellulose, and having a mean pore diameter of 1.5 to 2.2 nm, a BET specific surface area of 700 to 3000 m2/g, a mean particle size of 100 to 1100 ?m, a surface oxide content of 0.05 meq/g or greater and a packing density of 0.4 to 0.8 g/mL, and it can be used as a therapeutic or prophylactic agent for kidney disease or liver disease, for oral administration.

Abstract: The present invention provides a non-irritating, sprayable wound dressing composition and a non-irritating, non-sprayable ointment for treating wounds in mammals such as horses or dogs. The composition of the present invention is made of an acceptable carrier and an active ingredient made of organic salts of naturally occurring cations having the capacity to facilitate healing of wounds.

Abstract: This invention provides compounds of Formula 1, N-oxides and suitable salts thereof wherein R1 is Me, Cl, Br or F; R2 is F, Cl, Br, C1-C4 haloalkyl or C1-C4 haloalkoxy; R3 is F, Cl or Br; R4 is H; C1-C4 alkyl, C3-C4 alkenyl, C3-C4 alkynyl, C3-C5 cycloalkyl, or C4-C6 cycloalkylalkyl, each optionally substituted with one substituent selected from the group consisting of halogen, CN, SMe, S(O)Me, S(O)2Me, and OMe; R5 is H or Me; R6 is H, F or Cl; and R7 is H, F or Cl. Also disclosed are methods for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of Formula 1, an N-oxide thereof or a suitable salt of the compound (e.g., as a composition described herein).

Abstract: The present invention discloses alpha particle emitting, radioactive constructs capable of killing large tumors (>1 mm in diameter), or other cells involved in human or animal diseases such as virus infected cells, autoimmune cells, or other pathological cells, including normal cells, that are targets for destruction, to achieve a therapeutic result. The alpha-emitting constructs have high specific activity.

Abstract: A waterless composition suitable for delivery of an active agent to a body surface or cavity includes a vehicle having about 70% to about 99% by weight of a hydrophilic polar solvent, said hydrophilic solvent selected from the group consisting of (i) a mixture of two or more different polyethylene glycols (PEGs), wherein at least one PEG is a high molecular weight PEG having a melting point greater than 25° C.; and (ii) propylene glycol (PG); about 0% to about 10% of at least one surface active agent; about 0% to about 5% of a polymeric agent; about 0% to about 30% of a secondary hydrophilic solvent; and about 0% to about 5% of a silicone oil; and about 3% to about 25% hydrophobic propellant. The composition is otherwise substantially free of a hydrophobic solvent and includes at least one of a surface active agent and a polymeric agent. The vehicle and the propellant are sufficiently miscible that the components may be homogeneously distributed with mild shaking.

Abstract: The invention relates to a xenon-based anesthetic gas composition to be used, via inhalation, to maintain or preserve cerebral perfusion during an endarterectomy involving the clamping of the carotid artery in a mammal under general anesthesia. The xenon is preferably used in combination with at least one injectable anesthetic morphine agent such as remifentanil, sulfentanil, fentanyl, and alfentanil. Advantageously, the xenon is mixed with an oxygen-containing gas and administered to the patient after the patient has been anesthetized, put to sleep, and intubated. The use of xenon makes it possible to achieve a reduction in the pressure gradient during the clamping of the internal carotid artery relative to the usual anesthetic agents, and to achieve stable hemodynamics.

Abstract: An object of the present invention is to provide a scavenger of in vivo harmful reactive oxygen species and/or free radicals, which is capable of effectively reducing the concentrations of in vivo reactive oxygen species and/or free radicals and exhibiting given effects such as the suppression of aging process, the prevention of geriatric or lifestyle-related disease, health promotion, and the inhibition of oxidative stress by virtue of this reduction in the concentrations of reactive oxygen species and/or free radicals. The scavenger of in vivo harmful reactive oxygen species and/or free radicals of the present invention comprises a liquid or gas comprising at least a hydrogen molecule. This medium may further comprise an oxygen molecule. Furthermore, this medium may comprise water or an aqueous solution or may be a gas. The scavenger of reactive oxygen species and/or free radicals can be used in the treatment or prevention of a disorder attributed to reactive oxygen species and/or free radicals.

Abstract: Layered phyllosilicates are useful for adsorbing and/or binding to cholesterol and, thereby, reducing blood cholesterol in a patient. Accordingly, provided herein is a method of reducing hypercholesteremia in a mammal comprising administering to said mammal a protonated and at least partially exfoliated layered phyllosilicate material alone and in combination with other cholesterol-reducing agents in an amount effective to reduce hypercholesteremia in said mammal.

Abstract: The present technology provides a cell based assay for identifying compounds that modulate store-operated ionic calcium levels using itpr mutant cell lines, such as itpr-ku cells, which have abnormal ionic calcium levels.

Abstract: A premixed cement paste for use in medical or dental applications. The premixed cement paste remains fluid when stored in a hermetically sealed condition, but hydrates and hardens to set when placed in a physiological environment. The cement paste includes at least one calcium silicate compound and at least one substantially water-free liquid carrier mixed with the at least one calcium silicate compound; the substantially water-free liquid carrier avoids hydration of the mixture during storage, but undergoes exchange with aqueous physiological solutions so that the cement past hydrates and hardens to set when placed in a physiological environment. The paste may be placed in the physiological environment by injection, for example. The at least one calcium silicate compound may be, for example, calcium silicate, dicalcium silicate, tricalcium silicate, or mixtures thereof.

Abstract: The present invention is directed to a hemostatic material comprising a scaffold and a galvanic particulate. The galvanic particulate comprises particles made of at least two dissimilar metals. The scaffold is preferably a biocompatible polysaccharide-based hemostatic, such as a chitosan or cellulosic based hemostatic like ORC.

Abstract: A special prenatal nutritional supplement, characterized as containing active ingredients such as nutrients (including at least one or more vitamins), minerals, or a mixture of pharmaceutical and standard food material. The design method of this special prenatal nutritional supplement is that the type and dosage of the ingredients are defined each day in accordance with the chronological order of the development of the fetus. The product is arranged or displayed like a calendar in a day by day order.

Abstract: Chronic obstructive pulmonary disease (COPD), characterized by chronic airflow limitation, is a serious and growing public health concern. The major environmental risk factor for COPD is cigarette smoking, but the biological mechanisms underlying COPD are not well understood. Herein, proton nuclear magnetic resonance (1H-NMR) spectroscopy is used in methods to identify metabolites and biomarkers associated with lung function in COPD.

Abstract: Cigarette smoking is a primary determinant of chronic obstructive pulmonary disease (COPD), which is the fourth leading cause of morbidity and mortality in the United States. Unique proteins associated with COPD capable of differentiating subjects likely to experience rapid (RPD) or slow (SLW) decline in lung function have been identified using comprehensive high-throughput proteomic approaches. Thirty peptides, which mapped to 21 unique proteins, were linearly associated with annualized rates of lung function decline among smokers with COPD characterized as having rapid or slow decline and smokers without COPD. Using three different statistical approaches to assess the data, the RPD and SLW groups are differentiated by 55 peptides, which mapped to 33 unique proteins. A number of the identified peptides are proteolytic fragments of proteins that are involved in the complement and/or coagulation systems, have anti-protease activity, or metabolic functions.

Abstract: The invention relates to methods of improving the osteoinductivity of calcium phosphate materials, to calcium phosphate materials having improved osteoinductivity as well as bone (re)generation scaffolds produced therefrom and to the use of such materials and scaffolds in methods of treatment.

Abstract: A producing method for a living organism-applicable hydrogen-contained fluid, which includes hydrogen molecules in living organism-applicable fluid enclosed in a container (2i) with hydrogen molecule permeability, is provided. This method includes a hydrogen exposing step of exposing hydrogen molecules to the container (2i) in which the living organism-applicable fluid is enclosed from the outside of the container without opening the container. The container with hydrogen molecule permeability is one that allows a dissolved hydrogen concentration of a normal saline solution to be 1 ppb or greater when the container filled with the normal saline solution is immersed for 5 hours in a volume of hydrogen water, which stably maintains an approximately saturated state (1.6 ppm at 20 C degrees under 1 barometric pressure) and is 20 times the content volume of the container.

Abstract: The present invention provides methods and compositions for treating, preventing, modifying (reducing), or managing bone cancer pain by cyclohexenone compounds.

Abstract: A medical food for the dietary management of depression and/or anxiety includes water containing from 0.0002 to 0.0278 mol. % of isotopologue HOD, preferably, from 0.0178 to 0.0278 mol. % of isotopologue HOD. Further, a method for the dietary management of depression and/or anxiety uses the step of administering to a subject in need thereof the medical food. Further, a method of the treatment of depression includes the steps of administering to a subject an antidepressant drug and administering to the subject the medical food. Further, a method of the treatment of anxiety includes the steps of administering to a subject an antianxiety drug and administering to the subject the medical food.

Abstract: A cream has at least two components, one of the components includes stable water clusters, and the cream is applied on a body to produce local surface effects, local deep effects, and non-local effects in the body.

Abstract: Methods for modulating responsiveness to increased oxygen levels in an at-risk subject identifying an at-risk subject; and before exposing the identified at-risk subject to an increased amount of oxygen, administering to the at-risk subject an anti-inflammatory agent wherein the responsiveness of the at-risk subject to said increased amount of oxygen is modulated as compared to the responsiveness of the at-risk subject to said increased amount of oxygen in the absence of said anti-inflammatory.

Abstract: A gas mixture for treatment of a mycobacterial infection and methods thereof, wherein the gas mixture comprises hydrogen. In certain applications, the gas mixture further comprises oxygen and optionally an inert or anaerobic gas, preferably selected from the group consisting of nitrogen, helium, argon, carbon dioxide, and mixtures thereof. The methods for treatment comprise direct inhalation of the gas mixture comprising hydrogen and oxygen, intubation of a patient with a double lumen endotracheal tube thereby supplying one lung with an anaerobic gas, and administration of a gas mixture comprising hydrogen and oxygen in a hyperbaric setting. Also provided is a method of sterilization of a mycobacterium-contaminated surface comprising administration of the hydrogen-containing gas mixture.

Abstract: This invention relates to aqueous solutions of reactive chlorine compounds having the empirical formulae H2Cl2O6 or ClO3H, for example, and the derivatives, anions or salts thereof. The invention further relates to methods for the production of said compounds and the use thereof in the pharmaceutical and particularly in the medical field, in cosmetics, medicinal care and in the domains of food technology and technology.

Abstract: An adsorbent for an oral administration, comprising a spherical activated carbon wherein an average particle diameter is 50 to 200 ?m, a specific surface area determined by a BET method is 700 m2/g or more, and a bulk density is less than 0.54 g/mL is disclosed. The adsorbent for an oral administration has a high adsorbability, and is capable of adsorbing a large amount of toxins during a retention period in an intestine, and of remarkably increasing an adsorption amount of compounds having a large molecular weight.

Abstract: A medical device (40) including a collagenous biomaterial (10) for causing embolus and treating an aneurysm. The collagenous biomaterial (10) includes a small intestine submucosa (12) that is configured into various components (16) for causing a vascular occlusion or a packing aneurysm lumen.

Abstract: The present technology provides synthesized particles that mimic key structural and functional features of red blood cells. Such RBC-mimicking particles possess the ability to carry oxygen (and carbon dioxide) and flow through capillaries smaller than their own diameter. Further, such particles can also deliver drugs and imaging agents. These particles provide a new paradigm for the design of drug delivery and imaging carriers since they combine the functionality of natural RBCs with the broad applicability and versatility of synthetic drug delivery particles. Further, such particles can be used for detoxification and other biomedical applications.

Abstract: The invention encompasses antidotal food products containing activated charcoal for ingestion into the gastrointestinal tract of a user for treating various gastrointestinal disorders. The antidotal food product is orally administered having the visual appearance and physical properties which enables the desire on the part of young children to chew and ingest the food product.

Abstract: The invention relates to novel microemulsions comprising a non-polar lipid, at least one polar solvent, a surfactant, and a polar lipid. A microemulsion of these ingredients provides an environment that substantially encloses airborne particles, and it can be used for entrapping such particles. The inventive microemulsions are especially adapted for the prevention of symptoms in mammals, which are indirectly or directly caused by airborne particles. The invention further provides compositions comprising such microemulsions and methods of treatment comprising administering the same.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one thrombolytic agent (A), such as the human recombinant form of tissue-type plasminogen activator (rt-PA), and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon, and mixtures thereof, as a combined composition for simultaneous, separate or sequential use for treating ischemia. The present invention also relates to the use of at least one thrombolytic agent (A), such as the human recombinant form of tissue-type plasminogen activator (rt-PA), and at least one gas (B) selected from the group consisting of nitrous oxide, argon, xenon, helium, neon, and mixtures thereof, for the preparation of a combined pharmaceutical composition for treating ischemia.

Abstract: The present invention relates to a method for treating acute and chronic sinusitis, and in particular, severe chronic sinusitis by exposing affected tissue of the sinus and contiguous tissue in the, nasal cavity and greater oral cavity to effective amounts of chlorine dioxide as a bioactive agent. Compositions and methods of treatment are disclosed herein.

Abstract: This invention provides novel antimicrobial peptides and formulations thereof. The peptides and/or formulations are effective to kill or to inhibit the growth and/or proliferation of various bacteria, yeast, and fungi.

Abstract: There is disclosed therapeutic devices or sanitary articles intended for the treatment of diseases and/or disorders of the tonic/postural system, containing a composition which emits and/or reflects light energy in the far infrared spectrum and which includes a ceramic material. Also disclosed is the use of a composition which emits and/or reflects light energy in the far infrared spectrum and which includes a ceramic material in the preparation of therapeutic devices or sanitary articles intended for the treatment of diseases and/or disorders of the tonic/postural system, in particular, orthodontic devices, glasses and plasters.

Abstract: A composition and methods of its use, the composition comprising: a halogen source, urea, and an additional halogen stabilizer excluding urea, optionally an alkali in a concentration sufficient to provide said composition with a pH of greater than 10; and optionally excluding a stabilized bromine compound from said composition is disclosed. Additionally, a method for reducing biological activity in a process stream is disclosed. The method comprises: providing a composition to a process stream, wherein said composition contains: a halogen, urea, and an additional halogen stabilizer excluding urea, optionally an alkali in a concentration sufficient to provide said composition with a pH of greater than 10; and optionally excluding a stabilized bromine compound from said composition. The invention is also directed to compositions and methods of their use as effective biocidal agents for water streams.

Abstract: Disclosed herein are aptamers that comprise a nucleic acid sequence that has a specific affinity for a target. These aptamers can be used as delivery vehicles to deliver specific agents to particular sites. Alternatively, targeted aptamers can also be used with detection techniques to determine the presence of absence of specific targets in heterogeneous backgrounds.

Abstract: The bone graft system comprises a solid inorganic component, which is bone graft material, and a hydrogel. The hydrogel contains >2 ppm of silicon ions, calculated as parts by weight of Si per million of the aqueous component of the hydrogel. Preferably, the solid inorganic component comprises hydroxyapatite or a silicon-containing hydroxyapatite, and may be a silicon-containing hydroxyapatite having a Ca/P ratio in the range 2.05 to 2.55 and a Ca/(P+Si) molar ratio less than 1.66. Bone healing is promoted by delivery of silicon ion release from the hydrogel and by the solid inorganic component stimulating cell behavior.

Abstract: The present invention provides the use of nanoparticles of a compound of general formula MnXy, where M is (i) a metal selected from the group consisting of Calcium (Ca), Aluminium (Al), Zinc (Zn), Nickel (Ni), Tungsten (W) or Copper (Cu); or (ii) a non-metal selected from the group consisting of Silicon (Si), Boron (B) or Carbon (C); in which n is equal to 1, 2, or 3, and X is (iii) a non-metal selected from the group consisting of Oxygen (O), Nitrogen (N), or Carbon (C); or (iv) an anion selected from the group consisting of phosphate (PO43?), hydrogen phosphate (HPO42?), dihydrogen phosphate (H2PO4?), carbonate (CO3), silicate (SiO42?), sulphate (SO42?), nitrate (NO3?), nitrite (NO2?); in which y is equal to 0, 1, 2, 3 or 4; for use in reducing and/or preventing virus transmission. Articles of protective clothing or filters are provided in which the fibres are coated with said nanoparticles for use in reducing and/or preventing virus transmission.

Abstract: The present invention is directed to a dietary supplement comprising palatinose or a derivative thereof. The dietary supplement may be a nutritional product, a sports performance product, a weight loss product or a meal replacement product. The present invention is also directed to a method of increasing the absorption of a compound into the bloodstream, cells and tissue comprising administering palatinose, or a derivative thereof, in combination with the compound.

Abstract: The invention relates to a gaseous inhalable medicament containing xenon or N2O as active ingredient for use by inhalation for preventing and/or for treating neuropathic pain or pains caused by at least one cancer chemotherapy substance administered to a patient suffering from cancer, in particular a patient suffering from breast cancer, lung cancer, ovarian cancer, prostate cancer, colon cancer, rectal cancer or a gastric cancer or cancer of the upper aerodigestive tracts. The cancer chemotherapy substance contains one or more compounds chosen from platinum salts, taxanes, alkaloids, thalidomide and bortezomib, in particular paclitaxel, docetaxel or oxaliplatin. The effective volume proportion of nitrous oxide or of xenon is between 5 and 70%.

Abstract: The present invention constitutes dialysate formulations that are suitable for use in preparing dialysate solutions for use in batch and/or proportioning systems and for improving dialysis efficiency by reducing or preventing clotting of the dialysis flow paths. The dialysate chemical formulations for one batch of dialysate comprise an acid concentrate stored in a first vessel, and a citrate-containing bicarbonate concentrate stored in a second vessel. The contents of the first and second vessels are emptied into a dialysate preparation tank and mixed with water to form a batch quantity of dialysate solution. Alternately, a dry acid and/or a dry citrate-containing base concentrates are dissolved separately in measured quantities of water to form liquid concentrates which are then used in conjunction with a proportioning machine to generate on-line a final dialysis solution stream.

Abstract: Methods of sepsis in a sample from a patient are provided. Methods of detecting changes in expression of one or more RNAs associated with sepsis are also provided. Compositions and kits are also provided.

Abstract: An object of the present invention is to provide an enhancing agent for effect of anticancer agent for achieving an excellent therapeutic effect on cancer. The enhancing agent for effect of anticancer agent according to the present invention which is a solving means therefor is characterized in that a nitric oxide donor is an effective ingredient. In accordance with the present invention, an excellent therapeutic effect is able to be achieved on non-small cell lung cancer which is still in such a state that no effective therapeutic method has been established yet for a progressive cancer which is not operable and is one of cancers where chemotherapy is most difficult to apply.

Abstract: A process for producing a biocompatible material includes the steps of mixing an extract of a fish scale-derived hydroxyapatite (with water content of 70 to 75% by weight) and of a fish scale-derived collagen (with water content of 40 to 60% by weight) in the weight percent ratio of about 8:2, stirring the mixture and drying the mixture by a hot blast in order to obtain a composite.

Abstract: Disclosed are phospholipid based compositions and implant devices, as well as methods and kits that include such compositions or components thereof. In particular, the present compositions include a polymer component such as a poloxamer or PEG component and a phospholipid component, such as a Phosal. The present compositions may include at least one additional component, such as granules, powder and/or particulates. The present compositions may further include one or more bone graft materials and/or active ingredients. The compositions may be used on their own or incorporated on or in a surgical implant.

Abstract: A nutritional supplement includes the primary ingredients: N-acetyl D-glucosamine, cracked cell wall Green Chlorella, Licorice Root Extract, and Potassium Citrate, as well as secondary ingredients: Zinc L-Carnosine, Gamma-Oryzanol and Capsaicin, that improves the bodies uptake, utilization and over-all bioavailability of exogenous target protein fractions (TPF) including but not limited to: glycoproteins, (such as glucosamine) protein isolates as amino acids, glycosaminoglycans (GAG) (including proteoglycans, and mucopolysaccharides), and polysaccharides such as hyaluronic acid (hyaluronan). The biochemical interactions of the composition improves zeta potential for TPF incorporation in the body through direct and indirect interaction with primary cellular and digestive sites of multiple species.

Abstract: Methods of treating or reducing biofilms, treating a biofilm-related disorder, and preventing biofilm formation using D-amino acids are described.

Abstract: The invention relates to a gas composition containing xenon gas for use in preventing the relapse of a patient who has been weaned from at least one psychotropic product which resulted in said patient becoming habituated, the xenon being administered to the patient by inhalation. The composition of the invention contains an effective volume proportion of xenon, in particular from 5 to 70% by volume of xenon. DRAWING: FIG.

Abstract: An aerosol composition comprising: 0.01 wt % to 1.00 wt % sodium borate; 0.01 wt % to 1.50 wt % polyglycerol ester surfactant; <30 wt % propellant; and 67.5 wt % to 85.0 wt % water. Methods of manufacture of an aerosol air freshener are also described wherein the aerosol composition further comprises a fragrance.

Abstract: The present invention relates to methods and compositions for the modulation of wound healing and/or the production of extracellular membrane components by modulating the activity and/or amount of secreted protein acidic and rich in cysteine (SPARC) protein. The invention further provides methods for identifying compounds useful in the above-mentioned methods and compositions.

Abstract: A method of treating, reducing, or inhibiting biofilm formation by bacteria, the method comprising: contacting an article with a composition comprising an effective amount of a D-amino acid, said composition being essentially free of the corresponding L-amino acid, thereby treating, reducing or inhibiting formation of the biofilm, wherein the D-amino acid is selected from the group consisting of D-alanine, D-cysteine, D-aspartic acid, D-glutamic acid, D-histidine, D-isoleucine, D-lysine, D-leucine, D-asparagine, D-proline, D-glutamine, D-arginine, D-serine, D-threonine, D-valine, D-tryptophan, D-tyrosine, and a combination thereof.